Corcept Therapeutics Hit with Securities Class Action After FDA Finds Relacorilant Efficacy Gaps

Corcept faces a securities class action after the FDA finds gaps in evidence for its lead drug relacorilant.

Regulatory Setback Sparking Class Action

Robbins Geller Rudman & Dowd LLP is filing a class action, captioned Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), on behalf of purchasers of Corcept common stock between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges Corcept and certain executives violated the Securities Exchange Act by repeatedly representing that the relacorilant New Drug Application (NDA) was supported by strong evidence, was nearing approval and faced no FDA concerns, while allegedly knowing the agency had raised substantive adequacy issues.

The suit centers on relacorilant, Corcept’s lead candidate for indications including hypercortisolism (Cushing’s syndrome). Plaintiffs say Corcept disclosed on Dec. 31, 2025 that the FDA issued a Complete Response Letter (CRL) saying the agency could not reach a favorable benefit-risk assessment without additional evidence of effectiveness. A redacted CRL published by the FDA on Jan. 30, 2026 is cited in the complaint as further detailing that submitted clinical studies were insufficient to demonstrate efficacy and noting the agency had informed Corcept “on several occasions” about adequacy concerns during pre-submission meetings.

The complaint contends Corcept’s public statements masked a known material risk that the NDA would not be approved and that investors relied on optimistic characterizations of the regulatory pathway. Plaintiffs allege those disclosures caused investor losses and are seeking lead plaintiff status; Robbins Geller invites affected investors to submit claims via its website or contact its attorney in charge. Corcept does not comment in the filing included in the complaint summary, and the litigation is in its early stages.

Earnings and Clinical Milestones in Focus

Corcept is scheduled to report quarterly results on Feb. 24, 2026, and market participants are expected to focus on product sales, cash position, and management’s outlook. Investors and analysts are likely to scrutinize commentary on marketed therapy performance and any updates on capital allocation or potential financing moves in light of the regulatory setback.

Clinical and pipeline developments are also in sharper relief following the CRL. Management’s discussion of relacorilant’s next regulatory steps, plans for additional efficacy data, and timelines for potential resubmission will materially influence the company’s near-term strategy and investor assessments.